Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

BACKGROUND: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab and docetaxel in the neoadjuvant setting. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiong, Jiang, Zefei, Liu, Zhenzhen, Yang, Benlong, Yang, Hongjian, Tang, Jinhai, Wang, Kun, Liu, Yunjiang, Wang, Haibo, Fu, Peifen, Zhang, Shuqun, Liu, Qiang, Wang, Shusen, Huang, Jian, Wang, Chuan, Wang, Shu, Wang, Yongsheng, Zhen, Linlin, Zhu, Xiaoyu, Wu, Fei, Lin, Xiang, Zou, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795751/
https://www.ncbi.nlm.nih.gov/pubmed/36575513
http://dx.doi.org/10.1186/s12916-022-02708-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795751/
https://www.ncbi.nlm.nih.gov/pubmed/36575513
http://dx.doi.org/10.1186/s12916-022-02708-3

Ejemplares similares